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morbidities play a major role in driving antidyslipidemic use in
primary care setting.
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OBJECTIVES: SHAPE is designed to predict long-term clinical
outcomes of management with rimonabant of cardiovascular
risk in overweight or obese subjects. It is a lifetime Markov
model with monthly cycles incorporating at risk, diabetes, car-
diovascular disease and mortality states, and using Framingham
and UKPDS risk equations. The objective of this study was to
derive utility estimates for the model’s health states based on
patients similar to those in rimonabant’s trials. METHODS:
Mean health utility (EQ5D) values were obtained from 36,294
subjects in the Health Outcomes Data Repository Database
(HODaR) of whom 4991 had either an MI, stroke, TIA or
angina event with no previous inpatient history. The HODaR
project collects data from patients who have attended the Cardiff
and Vale NHS Trust in Wales. Utility values associated with spe-
ciﬁc BMI levels were also derived from multivariate analysis on
subjects with a BMI ≥27 kg/m2 adjusting for age, sex and dia-
betes status. RESULTS: Mean age-related health utility was
0.719 for an acute MI event, 0.709 for stroke, 0.698 for TIA,
0.709 for angina and 0.776 for diabetes (with no prior compli-
cations or inpatient history). Mean age adjusted utility decre-
ments associated with these end points were 0.072, 0.185, 0.088,
0.126 and 0.041 for acute MI, stroke, TIA, angina and diabetes
respectively. For BMI, a decrement of 0.014 utilities was esti-
mated and this decrement reﬂects a 1 unit increase in BMI. CON-
CLUSION: This study provides contemporary and relevant
utility values for cardiovascular modeling. The values were
derived from clinical endpoints matching those included in the
model and are well suited to models using Framingham or
UKPDS risk equations.
PCV81
VALIDATION OF THE MODE OF ADMINISTRATION OF THE
MEDICATION COMPLIANCE QUESTIONNAIRE
Rosa K1, Fitzgerald KA1, Moller RA2
1Mapi Values USA LLC, Boston, MA, USA, 2Pﬁzer, New York, NY, USA
OBJECTIVES: The Medication Compliance Questionnaire
(MCQ) measures concepts that may be related to medication
compliance by investigating subjects’ motivation, barriers, atti-
tudes, and beliefs regarding compliance. In the current study, the
MCQ was administered in The Netherlands primarily via postal
survey. However, due to low response rate to postal surveys in
Italy, the MCQ was planned to be administered there primarily
via telephone interviews. The primary goal of the study was to
evaluate the equivalence of the postal mode of the MCQ against
the telephone interview mode, to determine whether the results
could be compared cross culturally. METHODS: Sixty subjects
in Italy who responded to a postal administration of the MCQ
were randomly assigned to one of two groups. Thirty subjects
were administered the MCQ again approximately one week later
by post and the remaining 30 subjects were administered the
questionnaire again approximately one week later by telephone.
RESULTS: As expected, results showed that the telephone mode
of administration resulted in more complete data. Mail admin-
istration resulted in per item missing data rates of 3.3–23.3%
while the phone administration yielded 100% response rates on
all except one question, which was missing only one response.
A difference in the consistency of responses across modes was
found, with more consistency observed in the same mode
between ﬁrst and second administrations compared to alternate
modes. There was also evidence of a response shift in the tele-
phone administration mode including evidence for socially desir-
able response bias. CONCLUSIONS: Based on the results of this
study, it is recommended that the results from the telephone
administration not be considered equivalent to the mail admin-
istration without further examination. It is not advised to make
direct comparisons of MCQ responses between countries
without taking the potential impact of mode of administration
into account.
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OBJECTIVE: To help health care decision-makers assess the
cost-effectiveness of HDL-c raising therapy, a model was devel-
oped to project lifetime clinical and economic beneﬁts of adding
an HDL-c raising drug in statin-treated patients with persistently
low HDL-c. METHODS: We developed a simulation model
made of two analytic decision sub-models. The ﬁrst sub-model
(Monte-Carlo) created a cohort of patients based on lipid levels
after drug treatment. The second sub-model (Markov) estimated
long-term clinical and cost outcomes (Framingham risk equa-
tions). Validation analyses were performed. RESULTS: Internal
validation: in patients with no history of CVD, the model pre-
dicted a 2 years risk of CHD events of 1.12% and 2.02% risk
for males and females respectively versus 1% and 2% in the
Framingham study. In patients with a history of CVD, the model
predicted 2-year risk of CHD events of 9.15% and 3.20% for
males and females respectively versus 10 and 3.5% respectively
in the published values. External validation: 1) in patients with
low HDL-c, the model predicted a 2.32% risk for CHD events
associated with each 1 mg/dL increment in HDL-c versus 2–3%
in a published meta-analysis 2) by recreating the 4S cohort char-
acteristics and simvastatin treatment effects, the model predicted
cumulative incidences of 14.2% for non-fatal and 5.5% for fatal
CHD events versus 15.9% and 5.0% in the 4S. CONCLU-
SIONS: Based on our validations, this computer simulation
model appears to be a valuable and accurate tool to help evalu-
ate HDL-c raising therapy for patients with persistently low
HDL-c despite statin treatment.
PCV83
COMPLIANCE PATTERN OF PHARMACOLOGICAL REGIMENS
IN HYPERTENSIVES AND/OR DYSLIPIDEMIC PATIENTS IN
AMBULATORY CARE IN A SPANISH POPULATION
Sicras A1, Navarro R1, F Bobadilla J2, García M3
1Badalona Servicios Asistenciales, Barcelona, Spain, 2Pﬁzer Spain,
Madrid, Spain, 3Euroclin Institute, Alcobendas, Madrid, Spain
OBJECTIVES: Lack of adherence is a major determinant of
inadequate control of cardiovascular risk factors. The aim of this
study is to evaluate the level of therapeutic compliance among
patients with mild to moderate hypertension (HT) and/or dis-
lipidemia (DL), in a primary care setting in daily medical prac-
tice, and to determine factors associated with TC. METHODS:
